The biotech company Aromics recieves 1 M€ from the European Union to boost its drug against the asbestos-related hallmark cancer
13/02/2019
The European Commission has allocated, through the H2020-EIC-SMEInst-2018-2020-Phase 2 program, a total of 1,085.659€ to the BERMES project of Aromics, the objective of which is to complete the regulatory pre-clinical stage in order to begin studies in humans of the drug NAX035 for malignant mesothelioma, an aggressive and highly resistant cancer linked to asbestos exposur
+ info:
